What is it about?
This is the first documented case of such remarkable response to pazopanib among patients with RCC and brain metastasis with a recorded progression-free survival of 38 months.
Featured Image
Photo by Hal Gatewood on Unsplash
Why is it important?
In the Philippine setting where options for cancer treatment can be limited by the prohibitive cost of medications, this case can support the potential use of pazopanib as a potent agent for treating patients with RCC and brain metastasis. Pazopanib may prove to be a more sustainable option for patients. This case further highlights the need for more research on the potential role of pazopanib among patients with RCC and brain metastasis.
Perspectives
Writing this article has been a memorable experience for me as it strengthened my interest in Neuro-Oncology. I hope to publish more studies on this field and help more patients as a Neuro-oncologist in the near future. While there is still much to learn and discover on the diagnosis and treatment of brain tumors, this case is a beautiful reminder that miracles can happen everyday in the clinics.
Christianne Mojica
St. Luke's Medical Center
Read the Original
This page is a summary of: Prolonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report, Case Reports in Oncology, October 2021, Karger Publishers,
DOI: 10.1159/000519745.
You can read the full text:
Contributors
The following have contributed to this page
